News | February 21, 2025
Wanbury reports 88% drop in Q3 FY25 PAT
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
Krishna Institute of Medical Sciences Ltd enters into agreement with Splendid Hospitals
This strategic partnership will also enable KIMS to exercise call option (not an obligation) to acquire majority stake in UAIMS Hospital in the coming years
Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Profit after Taxes registered strong growth of 22% to Rs. 162 crores versus Rs. 134 crores in Q3 FY24
Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion
EBITDA grew by 11% on a YoY basis to Rs. 296 crore due to improved performance in CDMO Sterile Injectables, CRDMO and Generics
EBITDA grew 46.9% YoY to Rs. 210.3 crore with EBITDA margin at 18.2%, grew 401 bps YoY and the reported PAT at Rs. 90 crore
Subscribe To Our Newsletter & Stay Updated
